Company Description
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders.
We are developing verekitug, the only known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (“TSLP”), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
Preclinical and clinical data to date demonstrate verekitug’s highly potent inhibition of the TSLP receptor, which we believe will translate to a differentiated product profile, including improved clinical outcomes, substantially extended dosing intervals and the potential to treat a broad spectrum of patients.
We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plan to initiate development in chronic obstructive pulmonary disease.
| Country | United States |
| Founded | 2021 |
| IPO Date | Oct 11, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | E. Rand Sutherland |
Contact Details
Address: 890 Winter Street, Suite 200 Waltham, MA 02451 United States | |
| Phone | (781) 208-2466 |
| Website | upstreambio.com |
Stock Details
| Ticker Symbol | UPB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0002022626 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| E. Rand Sutherland, M.D., M.P.H. | Chief Executive Officer and Director |
| Michael Paul Gray, M.B.A. | Chief Financial and Operating Officer |
| Aaron Deykin, M.D. | Chief Medical Officer and Head of Research and Development |
| Adam Houghton, Ph.D., M.B.A. | Chief Business Officer |
| Ronald C. Renaud, Jr., M.B.A. | Chairman of the Board |
| Erez Chimovits, M.B.A., M.Sc. | Director |
| H. Edward Fleming, Jr., M.D. | Director |
| Dayton Misfeldt+ | Director |
| Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A. | Director |
| Marcella Kuhlman Ruddy, M.D., M.S. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 11, 2024 | 424B4 | Prospectus |
| Oct 10, 2024 | EFFECT | Notice of Effectiveness |
| Oct 10, 2024 | S-1MEF | Registration adding securities to prior Form S-1 registration |
| Oct 10, 2024 | CERT | Certification by an exchange approving securities for listing |
| Oct 8, 2024 | 8-A12B | Registration of securities |
| Oct 7, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 18, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Aug 9, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |